A180400 Stock Overview
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Dx & Vx Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,410.00 |
| 52 Week High | ₩10,050.00 |
| 52 Week Low | ₩3,690.00 |
| Beta | 0.0030 |
| 1 Month Change | -7.74% |
| 3 Month Change | -13.02% |
| 1 Year Change | -37.80% |
| 3 Year Change | n/a |
| 5 Year Change | -43.02% |
| Change since IPO | -8.88% |
Recent News & Updates
Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% Hiding
Mar 18
Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of Debt
Mar 08Shareholder Returns
| A180400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.3% | 2.4% | 0.6% |
| 1Y | -37.8% | 11.1% | 6.9% |
Return vs Industry: A180400 underperformed the KR Biotechs industry which returned 11.1% over the past year.
Return vs Market: A180400 underperformed the KR Market which returned 6.9% over the past year.
Price Volatility
| A180400 volatility | |
|---|---|
| A180400 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A180400 has not had significant price volatility in the past 3 months.
Volatility Over Time: A180400's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 131 | Yong Gu Lee | www.dxvx.com |
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It also provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs.
Dx & Vx Co., Ltd. Fundamentals Summary
| A180400 fundamental statistics | |
|---|---|
| Market cap | ₩133.26b |
| Earnings (TTM) | -₩27.48b |
| Revenue (TTM) | ₩46.75b |
2.9x
P/S Ratio-4.8x
P/E RatioIs A180400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A180400 income statement (TTM) | |
|---|---|
| Revenue | ₩46.75b |
| Cost of Revenue | ₩35.93b |
| Gross Profit | ₩10.82b |
| Other Expenses | ₩38.30b |
| Earnings | -₩27.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -909.45 |
| Gross Margin | 23.14% |
| Net Profit Margin | -58.79% |
| Debt/Equity Ratio | 135.2% |
How did A180400 perform over the long term?
See historical performance and comparison